CMS proposes that issuers of standardized plan options must place all covered generic drugs in the standardized plan options’ generic drug cost-sharing tier.
The medication treats depression, panic attacks, obsessive-compulsive disorder, bulimia and a severe form of premenstrual syndrome (premenstrual dysphoric disorder).